EFFECTS OF EZETIMIBE ON ABSORPTION OF DIETARY FATTY ACIDS-GCRC PILOT STUDY

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 依折麦布是FDA批准的治疗高胆固醇血症的药物，它通过抑制肠道对胆固醇的吸收来发挥作用。然而，最近在小鼠身上的一项研究表明，依折麦布也显著减少了饮食饱和脂肪酸的吸收，从而对饮食诱导的肥胖具有抵抗力。 在这项先导性研究中，我们将使用非侵入性的蔗糖聚苯乙酸酯方法来测量健康受试者在服用依折麦布一个月前和一个月后对个别膳食脂肪酸的肠道吸收。DNA也将被收集和储存，以供将来分析对脂肪酸吸收的遗传影响。 我们假设ezetimibe将减少人类对饱和脂肪酸的吸收，如果是这样的话，最终可能在预防肥胖症和2型糖尿病方面发挥作用。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Ezetimibe is an FDA approved drug for the treatment of hypercholesterolemia, which acts by inhibiting the intestinal absorption of cholesterol. However, a recent study in mice has shown that ezetimibe also significantly reduces the absorption of dietary saturated fatty acids, thereby conferring resistance to diet-induced obesity. In this pilot study we will use the non-invasive sucrose polybehenate method to measure the intestinal absorption of individual dietary fatty acids in healthy subjects before and after one month of treatment with ezetimibe. DNA will also be collected and stored for future analysis of genetic effects on fatty acid absorption. We hypothesize that ezetimibe will reduce the absoption of saturated fatty acids in humans, and if so, could ultimately have a role in the prevention of obesity and type 2 diabetes.